Future Directions in PSMA-PET Imaging

Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.

EP: 1.Overview of Advances in Imaging in Prostate Cancer

EP: 2.The Impact of PSMA-PET Imaging in Prostate Cancer

EP: 3.Identifying the Right Patient Population for PSMA-PET Imaging

EP: 4.PSMA-PET Imaging in the Biochemical Recurrence Setting

EP: 5.The Impact of PSMA-PET Imaging on Treatment Decisions

EP: 6.The Role for PSMA-PET Imaging in Active Surveillance

EP: 7.When and How Often PSMA-PET Imaging Should be Used

EP: 8.Monitoring Treatment Response

EP: 9.Unmet Needs and Challenges in Imaging of Prostate Cancer

EP: 10.The Value of Multidisciplinary Care in PSMA-PET Imaging

Now Viewing

EP: 11.Future Directions in PSMA-PET Imaging

EP: 12.PSMA-PET Imaging for Prostate Cancer: Perspectives From a Nuclear Radiologist

EP: 13.Similarities and Differences Among PSMA-PET Tracers

EP: 14.Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging Results

Related Videos

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.